Stifel Nicolaus Forecasts Strong Price Appreciation for DRI Healthcare Trust (TSE:DHT.UN) Stock

Key Points

• Stifel Nicolaus raised DRI Healthcare Trust’s price target to C$26 from C$25 while maintaining a “buy” rating, implying 36.13% upside from the prior close.
• Analyst sentiment is broadly positive: DRI Healthcare Trust has a consensus “Buy” rating and an average price target of C$25.20, with targets from other firms ranging from C$23 to C$30.
• The units rose to C$19.10 in Tuesday trading, near the 52-week high of C$19.75. The trust has a market capitalization of approximately C$1.05 billion and invests in pharmaceutical royalty streams.

DRI Healthcare Trust (TSE:DHT.UN - Get Free Report) had its target price hoisted by stock analysts at Stifel Nicolaus from C$25.00 to C$26.00 in a note issued to investors on Tuesday,BayStreet.CA reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target would indicate a potential upside of 36.13% from the stock's previous close.

Several other research analysts have also commented on DHT.UN. Canaccord Genuity Group increased their price target on shares of DRI Healthcare Trust from C$22.25 to C$23.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Raymond James Financial lifted their price objective on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the company a "strong-buy" rating in a research note on Monday, June 29th. Scotiabank upped their price objective on shares of DRI Healthcare Trust from C$25.00 to C$30.00 and gave the stock a "sector outperform" rating in a report on Tuesday, May 19th. Finally, National Bank Financial increased their target price on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock an "outperform" rating in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of C$25.20.

DRI Healthcare Trust Price Performance

DHT.UN traded up C$1.09 during midday trading on Tuesday, hitting C$19.10. 94,322 shares of the company's stock traded hands, compared to its average volume of 58,234. The company has a market cap of C$1.05 billion, a PE ratio of -21.22 and a beta of 0.35. The stock's fifty day simple moving average is C$18.09 and its 200-day simple moving average is C$17.05. DRI Healthcare Trust has a one year low of C$13.90 and a one year high of C$19.75.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is managed by DRI Capital Inc DRI a pioneer in global pharmaceutical royalty monetization. We provide uniquely favorable exposure for investors in the biopharma industry managing a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world and aiming to acquire dependable patent-protected cash flow streams derived from the sales of those important drugs while limiting the risks and costs connected to drug development. DRI has developed a disciplined strategy predicated on actively sourcing royalty streams on medically necessary products and proudly work with multiple repeat deal partners.DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario pursuant to a declaration of trust dated October 21 2020 as amended.DRI Healthcare Trusts units are listed and trade on the Toronto Stock Exchange under DHT.UN in Canadian dollars and under DHT.U in U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source